Signal · Supply Chain & Logistics
Private equity firm Creador in talks to buy into generic drug co Leeford Health
What the source reported
Source-reportedPrivate equity firm Creador is in advanced talks to acquire a stake. The firm expects to invest ₹800 crore in Leeford Healthcare. This acquisition would value the generic drugmaker at ₹8,000-₹8,500 crore. Leeford Healthcare is a diversified pharmaceutical and wellness company. This deal marks the company's first ownership dilution to an external investor.
- Publication
- The Economic Times - Industry · Trade Publication
- Published
- 3rd August 2026
- Original report
- economictimes.indiatimes.com
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Supply Chain & Logistics
- Geography
- India
- Organisations
- None identified
- Collected
- 3rd August 2026 · 21:13
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Moderate (20.0/100). Strongest contributor: Likely Event Severity (12.0/30 points). Limiting factor: Geographic Breadth (0.0/10 points). Initial Confidence Low (28.28/100, data sufficiency: Partial). Strongest contributor: Source Authority (20.0/40 points). Limiting factor: Specificity (0.0/20 points).
- Strongest contributor
- Likely Event Severity
- Limiting factor
- Geographic Breadth